Pfizer Market Cap 2010-2025 | PFE

Pfizer market cap history and chart from 2010 to 2025. Market capitalization (or market value) is the most commonly used method of measuring the size of a publicly traded company and is calculated by multiplying the current stock price by the number of shares outstanding. Pfizer market cap as of August 22, 2025 is $147.14B.
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $147.142B $63.627B
Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $673.574B 44.07
Johnson & Johnson (JNJ) United States $431.791B 17.93
AbbVie (ABBV) United States $372.037B 19.89
Novartis AG (NVS) Switzerland $268.235B 14.53
Roche Holding AG (RHHBY) Switzerland $260.064B 0.00
Novo Nordisk (NVO) Denmark $254.416B 15.40
Merck (MRK) United States $218.231B 11.44
Sanofi (SNY) France $126.091B 12.49
Bayer (BAYRY) Germany $32.695B 6.16
Innoviva (INVA) United States $1.270B 12.52